Medicine
Drug-Drug Interactions Between Direct Oral Anticoagulants and Azole Antifungals
Quick fact
Azole antifungals like ketoconazole and itraconazole can increase the plasma concentration of certain DOACs (such as rivaroxaban) by up to 2-3 times, significantly elevating the risk of major bleeding.
Why this is interesting
You might think that taking a blood thinner and an antifungal together is routine, but the combination can be a recipe for internal bleeding. How can an antifungal make a blood thinner more dangerous?
Read the full explanation
Understanding Drug-Drug Interactions Between Direct Oral Anticoagulants and Azole Antifungals
When your body processes a drug, it uses enzymes to break it down so it can be eliminated. One key enzyme is CYP3A4, found in the liver and intestine. Many DOACs, like rivaroxaban and apixaban, rely on CYP3A4 for their metabolism. Azole antifungals—used to treat fungal infections—are strong inhibitors of CYP3A4. They 'clog' the enzyme, slowing the breakdown of the DOAC. As a result, the DOAC stays in your bloodstream longer and at higher levels than intended. Additionally, azoles also block a transport protein called P-glycoprotein, which helps pump drugs out of cells. This further increases the DOAC concentration. In simple terms, the antifungal 'puts a brake' on the system that removes the blood thinner, turning a standard dose into an overdose. That can lead to excessive bleeding, which may be life-threatening.
A deeper explanation
The interaction is rooted in the competitive inhibition of CYP3A4 and P-glycoprotein (P-gp). Azoles bind to the heme iron of CYP3A4, preventing the metabolism of substrates like DOACs. For example, rivaroxaban is both a CYP3A4 substrate and a P-gp substrate. When ketoconazole (a strong inhibitor) is co-administered, its AUC (area under the curve) increases by about 150-160%. Apixaban similarly increases by ~100% with ketoconazole. In contrast, fluconazole, a milder CYP3A4 inhibitor, has a lesser effect (e.g., on rivaroxaban, AUC increase ~30%), but may still be clinically relevant. The clinical consequence is a heightened risk of bleeding, including intracranial hemorrhage and gastrointestinal bleeding. Therefore, co-administration requires caution: either avoid the combination, reduce the DOAC dose, or select an alternative antifungal (e.g., echinocandins) or an alternative anticoagulant that is less dependent on these pathways. This interaction exemplifies the need for comprehensive medication review and the use of drug-interaction databases in clinical practice.